2017
Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer
O’Connor M, Morrow MMB, Hunt KN, Boughey JC, Wahner-Roedler DL, Conners AL, Rhodes DJ, Hruska CB. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. EJNMMI Research 2017, 7: 5. PMID: 28091980, PMCID: PMC5237435, DOI: 10.1186/s13550-017-0255-6.Peer-Reviewed Original ResearchBreast cancerBenign lesionsMolecular subtypesBreast lesionsTumor molecular subtypeOverall diagnostic performancePathologic sizeAnalyzable patientsTumor extentMalignant tumorsLesion extentBlinded fashionLesion sizeSestamibiMolecular breastPatientsLesionsAlternative radiotracersLesion uptakeAssessment scoresROC analysisCancerInterest analysisDiagnostic performanceExamination one
2012
Proof of concept for low‐dose molecular breast imaging with a dual‐head CZT gamma camera. Part II. Evaluation in patients
Hruska CB, Weinmann AL, Skjerseth C, Wagenaar EM, Conners AL, Tortorelli CL, Maxwell RW, Rhodes DJ, O'Connor MK. Proof of concept for low‐dose molecular breast imaging with a dual‐head CZT gamma camera. Part II. Evaluation in patients. Medical Physics 2012, 39: 3476-3483. PMID: 22755727, PMCID: PMC3376157, DOI: 10.1118/1.4719959.Peer-Reviewed Original ResearchConceptsMolecular breast imagingMBq TcDiagnostic accuracyIntrareader agreementMedian lesion sizeLesion detectionPatient studiesEffective radiation doseTelluride gamma cameraSimilar diagnostic accuracyAdequate lesion detectionAdjunct screening techniqueGamma cameraAdministered dosesCount densityClinical careSeparate cohortLesion sizeMBq injectionMolecular breastLow dosesPatientsDense breastsBreast lesionsDoses